Cologne-based Refoxy Pharmaceuticals Secures €9.1 Million to Advance Anti-Aging Therapies Led by Algarve Biomedical Center Research Collaborator

Refoxy Pharmaceuticals, a Cologne-based biotech company pioneering pre-clinical anti-aging and age-related disease therapies, has successfully closed a €9.1 million seed-extension funding round. The funding, spearheaded by Boehringer Ingelheim Venture Fund, will bolster the company’s efforts to develop groundbreaking FOXO3 therapeutics, particularly targeting Idiopathic Pulmonary Fibrosis (IPF).

Founded in 2020 by Wolfgang Link, a distinguished researcher affiliated with the Algarve Biomedical Center Research Institute, and Victor Bustos, Refoxy Pharmaceuticals is at the forefront of harnessing the therapeutic potential of FOXO3. This vital transcription factor plays a crucial role in maintaining biological homeostasis. Through its proprietary F.act finder platform, Refoxy identifies and develops molecules that modulate FOXO3 activity to combat complex diseases.

With a strong focus on fibrotic disorders, Refoxy aims to address the significant unmet medical need in treating IPF, a chronic lung disease characterized by progressive scarring and limited treatment options. The recent funding injection will accelerate the development of their innovative therapies, positioning the company as a leader in the field of anti-aging and fibrotic disease research.

Wolfgang Link’s collaboration with the Algarve Biomedical Center Research Institute underscores the institute’s commitment to advancing medical research and developing cutting-edge treatments for age-related diseases. This partnership highlights the global impact of the institute’s research efforts, contributing to significant breakthroughs in the fight against debilitating conditions like IPF.